COVID-19 testing, timeliness and positivity from ICMR's laboratory surveillance network in India: Profile of 176 million individuals tested and 188 million tests, March 2020 to January 2021.

Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: eCollection Cited Medium: Internet ISSN: 1932-6203 (Electronic) Linking ISSN: 19326203 NLM ISO Abbreviation: PLoS One Subsets: MEDLINE

Original Publication: San Francisco, CA : Public Library of Science

COVID-19 Testing*; COVID-19/*epidemiology; Humans ; Incidence ; India ; Laboratories ; Specimen Handling

Background: The Indian Council of Medical Research set up a pan-national laboratory network to diagnose and monitor Coronavirus disease 2019 (COVID-19). Based on these data, we describe the epidemiology of the pandemic at national and sub-national levels and the performance of the laboratory network.
Methods: We included surveillance data for individuals tested and the number of tests from March 2020 to January 2021. We calculated the incidence of COVID-19 by age, gender and state and tests per 100,000 population, the proportion of symptomatic individuals among those tested, the proportion of repeat tests and test positivity. We computed median (Interquartile range-IQR) days needed for selected surveillance activities to describe timeliness.
Results: The analysis included 176 million individuals and 188 million tests. The overall incidence of COVID-19 was 0.8%, and 12,584 persons per 100,000 population were tested. 6.1% of individuals tested returned a positive result. Ten of the 37 Indian States and Union Territories accounted for about 75.6% of the total cases. Daily testing scaled up from 40,000 initially to nearly one million in March 2021. The median duration between symptom onset and sample collection was two (IQR = 0,3) days, median duration between both sample collection and testing and between testing and data entry were less than or equal to one day. Missing or invalid entries ranged from 0.01% for age to 0.7% for test outcome.
Conclusion: The laboratory network set-up by ICMR was scaled up massively over a short period, which enabled testing a large section of the population. Although all states and territories were affected, most cases were concentrated in a few large states. Timeliness between the various surveillance activities was acceptable, indicating good responsiveness of the surveillance system.
Competing Interests: The authors have declared that no competing interests exist.

PLoS One. 2020 Dec 17;15(12):e0244053. (PMID: 33332461)
Int J Environ Res Public Health. 2021 Apr 27;18(9):. (PMID: 33925665)
Aging (Albany NY). 2020 May 29;12(10):9959-9981. (PMID: 32470948)
Indian J Med Res. 2020 May;151(5):424-437. (PMID: 32611914)
EClinicalMedicine. 2021 Feb;32:100717. (PMID: 33521608)
Lancet Infect Dis. 2020 May;20(5):533-534. (PMID: 32087114)
Int J Infect Dis. 2021 Jul;108:145-155. (PMID: 34022338)
BMC Public Health. 2020 Dec 29;20(1):1925. (PMID: 33372608)
Monaldi Arch Chest Dis. 2020 Nov 09;90(4):. (PMID: 33169598)
Postgrad Med J. 2021 May;97(1147):312-320. (PMID: 32978337)
Monaldi Arch Chest Dis. 2020 Apr 10;90(1):. (PMID: 32290644)
Model Earth Syst Environ. 2020 Oct 14;:1-7. (PMID: 33072850)
Lancet Glob Health. 2021 Mar;9(3):e257-e266. (PMID: 33515512)
J Ovarian Res. 2020 Nov 24;13(1):137. (PMID: 33234144)
Epidemiol Serv Saude. 2020 Dec 18;30(1):e2020788. (PMID: 33331603)
Semergen. 2020 Aug;46 Suppl 1:55-64. (PMID: 32571677)
Lancet Public Health. 2020 Aug;5(8):e452-e459. (PMID: 32682487)
SN Compr Clin Med. 2020 Jun 4;:1-3. (PMID: 32838138)
Indian J Med Res. 2020 Jul & Aug;152(1 & 2):61-69. (PMID: 32773414)
Lancet. 2017 Dec 2;390(10111):2437-2460. (PMID: 29150201)
Indian Econ Rev. 2021 May 27;:1-18. (PMID: 34075257)
Indian J Med Res. 2020 Jul & Aug;152(1 & 2):48-60. (PMID: 32952144)
Sci Data. 2020 Oct 8;7(1):345. (PMID: 33033256)

Date Created: 20211203 Date Completed: 20211214 Latest Revision: 20211214

20221213

PMC8641892

10.1371/journal.pone.0260979

34860841